Third-Trimester Pregnancy Complications

Primary Care - Clinics in Office Practice

Volumn 39, Issue 1, 2012, Pages 95-113

  Newfield, Emily ^a  

^a Training in Early Abortion for Comprehensive Healthcare   (United States)

Author keywords

Abruptio placentae; Antenatal; Hypertension; Placenta previa; Preeclampsia; Pregnancy; Preterm birth; Preterm labor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CLINDAMYCIN; DEXAMETHASONE; DILTIAZEM; HYDROXYPROGESTERONE CAPROATE; LABETALOL; MAGNESIUM; MAGNESIUM SULFATE; METOPROLOL; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; STEROID; UTERUS SPASMOLYTIC AGENT; VANCOMYCIN;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRAIN HEMORRHAGE; DECISION MAKING; DRUG DOSE COMPARISON; ECLAMPSIA; FEMALE; FERTILIZATION IN VITRO; HEALTH PRACTITIONER; HELLP SYNDROME; HUMAN; INFANT MORTALITY; KIDNEY FAILURE; LABOR COMPLICATION; LABORATORY TEST; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG EDEMA; MATERNAL HYPERTENSION; MORBIDITY; OVULATION INDUCTION; PATIENT CARE; PATIENT COUNSELING; PELVIC EXAMINATION; PHYSICAL EXAMINATION; PLACENTA PREVIA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PREMATURITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; PUERPERIUM; RECURRENCE RISK; RESPIRATION DEPRESSION; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SMOKING CESSATION; SOLUTIO PLACENTAE; STILLBIRTH; THIRD TRIMESTER PREGNANCY; URTICARIA; UTERINE CERVIX CERCLAGE; VAGINA BLEEDING; VAGINAL DELIVERY; VASA PREVIA;

EID: 84856585178     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.11.005     Document Type: Review

References (34)

1. Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Preterm birth: causes, consequences, and prevention 2006, National Academy Press, Washington, DC. R.E. Behrman, A. Stith (Eds.).
2. Martin J.A., Hamilton B.E., Sutton P.D., et al. Births: final data for 2007. Natl Vital Stat Rep 2010, 58(24):1-85.
3. Petrini J.R., Callaghan W.M., Klebanoff M., et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005, 105(2):267-272.
4. Iams J.D., Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010, 203(2):89-100.
5. Fonseca E.B., Celic E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. NEngl J Med 2007, 357:462-469.
6. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. NEngl J Med 2003, 348(24):2379-2385.
7. Rouse D.J., Caritis S.N., Peaceman A.M., et al. Atrial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. NEngl J Med 2007, 357(5):454-461.
8. Norwitz E.R., Caughey A.B. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011, 4(2):60-72.
9. American College of Obstetricians and Gynecologists. Management of Preterm Labor. ACOG practice bulletin no. 43. Obstet Gynecol 2003, 101(5 Pt 1):1039-1047.
10. Doyle L.W., Crowther C.A., Middleton P., et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009, 1. CD004661.
11. Crowther C.A., Hiller J.E., Doyle L.W., et al. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. JAMA 2003, 290(20):2669.
12. Högberg U., Holmgren P.A. Infant mortality of very preterm infants by mode of delivery, institutional policies and maternal diagnosis. Acta Obstet Gynecol Scand 2007, 86(6):693-700.
13. Sholapurkar S.L. Is there an ideal interpregnancy interval after a live birth, miscarriage or other adverse pregnancy outcomes?. JObstet Gynaecol 2010, 30(2):107-110.
14. Anonymous. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure and Pregnancy. Am J Obstet 2000, 183(1):S1-S22.
15. American College of Obstetricians and Gynecologists. Chronic hypertension in pregnancy. ACOG practice bulletin No. 29. Obstet Gynecol 2001, 98:177-185.
16. Seely E.W., Ecker J. Chronic hypertension in pregnancy. NEngl J Med 2011, 365(5):439-446.
17. Podymow T., August P., Akbari A. Management of renal disease in pregnancy. Obstet Gynecol Clin North Am 2010, 37(2):195-210.
18. Sethuram R., Kiran T.S., Weerakkody A.N. Is the urine spot protein/creatinine ratio a valid diagnostic test for pre-eclampsia?. JObstet Gynaecol 2011, 31(2):128-130.
19. Wheeler T.L., Blackhurst D.W., Dellinger E.H., et al. Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol 2007, 196(5). 465.e1-4.
20. Sibai B.M., Ramadan M.K., Usta I., et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993, 169(4):1000-1006.
21. Belfort M., Allred J., Dildy G. Magnesium sulfate decreases cerebral perfusion pressure in preeclampsia. Hypertens Pregnancy 2008, 27(4):315-327.
22. Sibai B.M. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004, 190(6):1520-1526.
23. Brown M.A., Mackenzie C., Dunsmuir W., et al. Can we predict recurrence of pre-eclampsia or gestational hypertension?. BJOG 2007, 114(8):984-993.
24. Hernandez-Diaz S., Toh S., Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009, 338:b2255.
25. Vikse B.E., Irgens L.M., Leivestad T., et al. Preeclampsia and the risk of end-stage renal disease. NEngl J Med 2008, 359(8):800-809.
26. Sibai B.M., El-Nazer A., Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986, 155(5):1011-1016.
27. Barton J.R., Stamsno G.J., Sibai B.M. Monitored outpatient management of mild gestational hypertension remote from term. Am J Obstet Gynecol 1994, 170:765-769.
28. Saudan P., Brown M.A., Buddle M.L., et al. Does gestational hypertension become pre-eclampsia?. BJOG 1998, 105(11):1177-1184.
29. Sibai B.M., Stella C.L. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009, 200(5). 481.e1-7.
30. Buchbinder A., Sibai B.M., Caritis S., et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. AmJ Obstet Gynecol 2002, 186(1):66-71.
31. Oyelese Y., Smulian J.C. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006, 107(4):927-941.
32. Publications Committee, Society for Maternal-Fetal Medicine, Belfort M.A. Placenta accreta. Am J Obstet Gynecol 2010, 203(5):430-439.
33. Oyelese Y., Ananth C. Placental abruption. Obstet Gynecol 2006, 108(4):1005-1016.
34. Nguyen C., Montz F.J., Bristow R.E. Management of stage I cervical cancer in pregnancy. Obstet Gynecol Surv 2000, 55(10):633-643.